Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00984204 · ClinicalTrials.gov registry record · Phase 3
Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)
A Phase 3 study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 3
- Development phase
- 188
- Enrollment target
NCT00984204 is a Phase 3 study that has completed, run by Abbott Medical Devices. The registered enrollment target is 188 participants.
The verdict
NCT00984204, a Phase 3 study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 188 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that ablation with the Therapy™ Cool Path™ Duo cardiac ablation system can eliminate typical atrial flutter and that its use does not result in an unacceptable risk of serious adverse events (SAE's).
Interventions
- DEVICE Therapy Cool Path Duo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00984204
The ClinicalTrials.gov registry entry for NCT00984204 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Therapy Cool Path Duo is the first listed.
NCT00984204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00984204 about?
NCT00984204 is a clinical study titled "Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)". The purpose of this study is to demonstrate that ablation with the Therapy™ Cool Path™ Duo cardiac ablation system can eliminate typical atrial flutter and that its use does not result in an unacceptable risk of serious adverse events (SAE's).
What is the current status of trial NCT00984204?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 188 participants. The study started on 2009-10. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00984204?
The interventions under investigation include: Therapy Cool Path Duo (DEVICE).
Who is sponsoring clinical trial NCT00984204?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.